Quote: The challenges of antitrust enforcement in health care

The complexity of this undertaking highlights a fundamental enforcement reality. If it’s this hard for regulators to demonstrate why a patently worrisome acquisition should be blocked, it is even less likely that they will investigate or attempt to halt mergers for which potential effects are unclear. […]

Consolidation will surely continue before we can determine whether it is benign.

Leemore Dafny, The New England Journal of Medicine

@afrakt

Share on twitter
Share on facebook
Share on linkedin
Share on reddit
Share on email

Hidden information below

Subscribe

* indicates required
Email Format